Gilead Sciences, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 113   

Articles published

GILD 88.94 +0.26 (0.29%)
price chart
The Biotech Bull Market Is Far From Over [Inovio Pharmaceuticals Inc, Gilead ...
One issue was drug-pricing concerns regarding Gilead Sciences Inc.'s (GILD:NASDAQ) Sovaldi (sofosbuvir), which was approved last December for the treatment of chronic hepatitis C virus (HCV) infection.
Related articles »  
Jim Cramer: Vertex Pharmaceuticals Incorporated (VRTX), Gilead Sciences, Inc ...
Then comes Gilead Sciences, Inc.(NASDAQ:GILD) which is in the news and stock trends. The reason behind this was the successful new drug by Gilead Sciences, Inc.(NASDAQ:GILD) for Hepatitis C. This drug can really give a breakthrough to Gilead ...
Related articles »  
The Biggest Beneficiary Of Biotech's Comeback
Somewhat ironically, a rollover in biotech stocks was one of the proximate causes of the overall sell-off in tech earlier this year.
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics ...
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Karopharm Therapeuticcs Inc, Methode Electronics Inc, Gilead Sciences Inc, and Nimble Storage Inc. Karyopharm Therapeutics Inc. (KPTI): CEO Michael Kauffman ...
Related articles »  
Traders Buzz: Twitter, Inc. (NYSE:TWTR), Gilead Sciences Inc. (NASDAQ:GILD ...
Twitter, Inc. (NYSE:TWTR)'s shares declined 1.55% to $37.47. The company on July 7 has appointed Katie Stanton its new media chief, placing the former Google executive at the heart of its crucial relationships with Hollywood and the global media ...
Related articles »  
Concerns At Biotech Stocks - Gilead Sciences, Inc. (NASDAQ:GILD), ACADIA ...
In last trading session, Gilead Sciences, Inc. (NASDAQ:GILD) after opening at $86.84 reached its intraday high price of $87.51 furthermore then closed at $87.11 by shares plummeted -0.11%.
Why Gilead Sciences Inc (NASDAQ:GILD) is Looming Near Buy Point with ...
Biotechs Gilead Sciences Inc (NASDAQ:GILD) and Anika Therapeutics (NASDAQ:ANIK) were amid just a few stocks in the Spotlight screen that are still looming near buy points.
Related articles »  
Company Update: Gilead Sciences, Inc. (NASDAQ:GILD) Submits Japan Approval
TheFlyOnTheWall.com repored this morning that Gilead Sciences, Inc. (NASDAQ:GILD), announced that the company has submitted a New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, a once-daily ...
Gilead Sciences, Inc. (NASDAQ:GILD) to seek approval to sell Sovaldi in Japan  Market News Call
Gilead Submits New Drug Application to Japan's Pharmaceutical and ...  Business Wire (press release)
Related articles »  
Gilead Sciences, Inc. (NASDAQ:GILD) is the Stock of the Week
Gilead Sciences, Inc. (NASDAQ:GILD) has been selected as the Stock of the Week by Stock Traders Daily this week. After recent eye popping increases in the stock price and corresponding increases in earnings the stock has become quite volatile and that ...
Biotech Stocks Bounce back To Green- Gilead Sciences, Inc. (NASDAQ:GILD ...  eMarketsDaily
Traders Stocks Alert: Gilead Sciences, Inc. (NASDAQ:GILD), RadioShack ...  Market News Call
Related articles »  
Why Investors Should Sell AbbVie And Buy Gilead Sciences
Given all the threats, investors should sell AbbVie and buy Gilead Sciences. AbbVie (ABBV) has put in a flat ... However, with competition from Gilead Sciences (GILD) in the cards, and patents about to expire, will AbbVie be able to sustain its ...
$1000-a-pill Sovaldi jolts U.S. health care system  Indiana Gazette
New Hepatitis C Drug's Cost A Steep Climb For Colorado  KUNC
Related articles »